COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

ISRAEL CANCER RESEARCH FUND INC

NEW YORK, NY · EIN 510181215 · Form 990 · FY2023 · Medium ($1M-$10M)
revenue
$7.7M
expenses
$6.4M
net assets
$16.0M
employees
12
volunteers
44
program ratio
67%
mission · from form 990

TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND.

profile · synthesized from sources

Nonprofit dedicated to advancing cancer research in Israel by funding Israeli scientists and fostering collaborations with North American institutions. Supports the development of early-career researchers through fellowships and career development awards. All programs are focused on strengthening Israel’s scientific capacity in oncology for the benefit of global health.

irs program accomplishments · form 990 part iii · fy2023

What they reported doing

  1. #1 primary $1.00M
    SUPPORT THE DEVELOPMENT OF THE NEXT GENERATION OF ISRAELI CANCER SCIENTISTS. ICRF IS COMMITTED TO FACILITATING THE DEVELOPMENT OF FUTURE CANCER SCIENTISTS IN ISRAEL. TOWARDS THIS END ICRF FUNDS THREE TYPES OF GRANTS: POSTDOCTORAL FELLOWSHIP AWARDS, RESEARCH CAREER DEVELOPMENT AWARDS, AND CLINICAL RESEARCH CAREER DEVELOPMENT AWARDS. FELLOWSHIPS SUPPORT MDS AND PHDS WHO HAVE JUST COMPLETED THEIR POSTGRADUATE TRAINING. THESE AWARDS CAN BE USED TO SUPPORT SALARIES OR RESEARCH COSTS, WHILE THESE INDIVIDUALS APPRENTICE IN THE LABORATORIES OF SENIOR INVESTIGATORS. CAREER DEVELOPMENT AWARDS ARE TO ENHANCE THE RESEARCH CAPABILITIES OF YOUNG ISRAELI SCIENTISTS IN THE FORMATIVE PHASE OF THEIR CAREERS. CANDIDATES MUST HAVE DEMONSTRATED OUTSTANDING POTENTIAL FOR CONTRIBUTIONS TO CANCER RESEARCH AND MUST EXHIBIT GREAT POTENTIAL TO BECOME INDEPENDENT INVESTIGATORS RESEARCH. SUPPORTING THESE NEWLY LAUNCHED SCIENTISTS, ENHANCES THEIR OPPORTUNITIES IN ISRAEL AND ALLOWS THEM TO OPTIMIZE THEIR WORK WITHOUT EMIGRATING TO OTHER ADVANCED COUNTRIES.
  2. #2 $409K
    SUPPORT COLLABORATIVE CANCER RESEARCH CONDUCTED BY ISRAELI SCIENTISTS IN ASSOCIATION WITH NORTH AMERICAN CANCER SCIENTISTS. CANCER SCIENCE OFTENTIMES REQUIRES MULTI-DISCIPLINARY APPROACHES, ENGAGEMENT WITH HIGHLY SPECIALIZED AREAS OF SCIENCE, AND EXPENSIVE EQUIPMENT THAT IS NOT EASILY ACCESSED. COLLABORATIONS BETWEEN SCIENTISTS IN ISRAEL AND NORTH AMERICA CAN ADDRESS THESE CHALLENGES, FOSTER UNEXPECTED SYNERGIES, AND ENHANCE BOTH INTELLECTUAL CURIOSITY AND INNOVATION. ICRF PROMOTES COLLABORATION BY SUPPORTING GRANTS THAT FUND PROMISING CANCER RESEARCH PROJECTS BEING CONDUCTED ON A COLLABORATIVE BASIS BETWEEN INVESTIGATORS IN ISRAEL AND AN AMERICAN OR CANADIAN RESEARCH INSTITUTION.
named programs · 4 · from sources

What they call their work

Clinical Research Career Development Awards
Funds clinician-scientists in formative career stages to strengthen clinical cancer research capacity in Israel
Collaborative Cancer Research Grants
Supports joint research projects between Israeli scientists and counterparts at North American institutions to promote innovation and resource sharing
Postdoctoral Fellowship Awards
Provides funding to Israeli PhDs and MDs immediately after postgraduate training to support salaries and research costs while working under senior investigators
Research Career Development Awards
Supports early-career Israeli scientists demonstrating high potential to become independent cancer researchers, enhancing their ability to remain in Israel
activities · 3 groups

What they do

  • Cancer Research Funding 4 activities
    • Funding collaborative cancer research between Israeli and North American institutions
      Supports joint research projects between scientists in Israel and investigators at research institutions in the United States and Canada to promote international scientific collaboration in cancer research.
    • Funding early-career Israeli cancer researchers through Career Development Awards
      Awards three-year Career Development Grants of up to $45,000 per year to early-career Israeli scientists conducting cancer research in Israel, supporting the growth of emerging research talent.
    • Funding independent cancer research projects in Israel through Project Grants
      Provides three-year Project Grants of up to $60,000 per year to independent investigators leading cancer research projects in Israel, covering a broad range of cancer types and research approaches.
    • Funding senior Israeli cancer researchers through Research Professorship Grants
      Provides five-year Research Professorship Grants of up to $100,000 per year to accomplished Israeli cancer researchers at the full professor level to sustain long-term, high-impact research programs.
  • Regional Chapter Network Support 1 activity
    • Organizing local chapters and community engagement to support cancer research
      Operates active chapters in the United States, Canada, and Israel that organize local events, volunteer leadership, and community outreach activities to raise awareness and funding for cancer research in Israel.
  • Uncategorized 2 activities
    • Funding artificial intelligence-driven cancer research in Israel
      Supports research initiatives in Israel that apply artificial intelligence, deep learning, and computational analysis to improve early detection, risk stratification, and treatment response prediction across multiple cancer types, including breast cancer, pancreatic cancer, and acute leukemia.
    • Supporting cancer research in Israel through a rigorous peer-review process
      Evaluates grant applications using a peer-review system modeled on the U.S. National Institutes of Health, assessing proposals based on scientific merit, innovation, and potential impact to ensure high-quality research funding.
financials · form 990 · fy2023
revenue
Total revenue$7.73M
Contributions & grants$7.78M101%
Program service revenue$00%
Investment income$203K3%
Other revenue$-259K
expenses
Total expenses$6.35M
Program expenses67%
Admin / overhead11%
Fundraising22%
Salaries & benefits$2.09M
Grants paid out$3.46M
Largest expense lineCompensation
balance sheet
Total assets$19.25M
Cash$5.60M
Investments$10.64M
Liabilities$3.28M
Net assets$15.97M
Liquid reserves30.7 mo
4 years on record · 2020–2023 · YoY revenue +34.8%
leadership · form 990 part vii · fy2023

Who runs it

paid leadership · 5
NameTitleHours/wkCompensation
BERYL CHERNOV NATIONAL EXECUTIVE DIRECTOR 40 $395K
ALAN HERMAN EXECUTIVE DIRECTOR, NEW YORK 40 $290K
ALLYSON MARKS-GREENFIELD EXECUTIVE DIRECTOR, CHICAGO 40 $188K
TANIA ORENSTEIN CONTROLLER 40 $179K
DAVID KWESKIN CONNECTICUT DIRECTOR 40 $123K
board members · 20
  • ALAN BERK — TRUSTEE
  • ARNOLD M BASKIES MD — VICE PRESIDENT
  • BARBARA KASELL — TRUSTEE
  • BONNIE E FISH — EXECUTIVE COMMITTEE MEMBER
  • BRAD GOLDHAR — TRUSTEE
  • BRUCE BARRON — TRUSTEE
  • BRYNA GOLDBERG — CHAIR
  • CHARLES BEN DAYAN — TRUSTEE
  • CHARLES SERLIN — EXECUTIVE COMMITTEE MEMBER
  • CYNTHIA PERL — SECRETARY
  • DAVID ABRAMSON — PRESIDENT
  • DAVID MALKIN MD — TRUSTEE
  • GARY I GRAD MD — TRUSTEE
  • GERELD SOFF MD — TRUSTEE
  • JEFFREY BERNSTEIN — TRUSTEE
  • JEFFREY BLY — TRUSTEE
  • JOEL PELOFSKY — TRUSTEE
  • JORDANNA FEIFER — EXECUTIVE COMMITTEE MEMBER
  • JULIA WEKSLER — TRUSTEE
  • KENNETH E GOODMAN — TRUSTEE
relationships · 20

Who they work with

  • American research institution Partner — Collaborative research partner for funded cancer research projects
  • Bennett Cancer Center Partner — Collaborates with medical professionals from the Bennett Cancer Center, including Dr. Steven Lo.
  • Breast Cancer Alliance Partner — Recognized Dr. Steven Lo for outstanding care and advocacy.
  • Canadian research institution Partner — Collaborative research partner for funded cancer research projects
  • Chaim Sheba Medical Center Partner — Hosts ICRF-funded researcher Dr. Debbie Anaby conducting AI-based breast cancer detection research.
  • Chicago Chapter of the Israel Cancer Research Fund Network — Local chapter operating under ICRF with a board and executive team in Chicago.
  • Dr. Daniel G. Miller Partner — Founding member and physician who initiated ICRF after observing the need to support Israeli scientists.
  • Josephberg’s Partner — Sponsor of the ICRF Sandy Herzfeld Memorial Golf Outing 2026, in honor of the Herzfeld family.
  • Moffitt Cancer Center Partner — Collaborates with researchers at Moffitt Cancer Center, including Dr. John E. Mullinax, who serves in leadership roles within ICRF’s Scientific Review Panel and International Scientific Council.
  • ProposalCentral Partner — Platform used for electronic submission and management of grant applications.
  • Rambam Medical Center Partner — Hosts ICRF awardee Dr. Ruth Perets, who is affiliated with this institution.
  • Ricki Herzfeld & Family Partner — Generous sponsor of the ICRF Sandy Herzfeld Memorial Golf Outing 2026.
  • Rolfe Pancreatic Cancer Foundation Partner — Co-hosts the Drive Fore Research Golf Classic with ICRF to support pancreatic cancer research.
  • Stamford Health Partner — Employer of honorees Dr. Frances Ginsburg and Dr. Steven Lo.
  • Sunningdale Country Club Partner — Host venue for the ICRF Sandy Herzfeld Memorial Golf Outing 2026.
  • Technion – Israel Institute of Technology Partner — Hosts ICRF-funded researcher Prof. Ron Kimmel applying deep learning to breast cancer risk stratification.
  • Temple Beth-El Partner — Venue host for the "An Evening of Hope 2026" event.
  • The V Foundation Partner — Collaborates with The V Foundation, as indicated by use of photo from their website in an ICRF news story.
  • U.S. National Institutes of Health (NIH) Partner — Models its peer-review process after the NIH's system.
  • Weizmann Institute of Science Partner — Hosts ICRF-funded researcher Prof. Ido Amit developing AI tools for predicting leukemia immunotherapy response.
strategies · 5

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • AI-Driven Precision Oncology
    methodology: ai-driven_cancer_research
    By applying artificial intelligence, machine learning, and advanced sequencing to cancer research, we improve detection, treatment prediction, and patient outcomes in sarcoma and other cancers, because Israel’s innovation ecosystem enables rapid translation of data-intensive technologies into clinical insights.
  • International Collaborative Innovation
    methodology: international research collaboration
    By funding partnerships between Israeli scientists and North American institutions, we enhance innovation in cancer research, because cross-border collaboration combines complementary expertise and resources to advance discovery beyond what either can achieve alone.
  • Leveraging High-Efficiency Research Environments
    methodology: high-efficiency_research_investment
    By investing in Israeli cancer research where overhead costs are lower and scientific productivity is high, we maximize the impact of early-stage funding, because efficient research ecosystems generate more discovery per dollar than traditional funding models.
  • Talent Retention Through Early-Career Support
    methodology: researcher-retention-through-funding
    By funding fellowships and mentored research for early-career scientists in Israel, we retain top scientific talent and reduce brain drain, because financial instability is a primary driver of researcher emigration and continuity in research teams accelerates breakthroughs.
  • Translational Research Acceleration
    methodology: translational_research
    By prioritizing foundational and high-impact research with clear pathways to clinical application, we accelerate the development of life-saving discoveries, because bridging the gap between basic science and patient care maximizes real-world impact within a 5–10 year horizon.